María Merino

María Merino

Auto-generated profile, based on publicly available information

María Merino

Health Outcomes Research Department, Weber, Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Economics & Human Biology
Verified
Journal Article
Closed access
MVMaría Merino Ventosa
María Merino Ventosa
Rosa Urbanos-GarridoRosa Urbanos-Garrido
Rosa Urbanos-Garrido

1 May 2017 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
JLJulio López-Bastida
Julio López-Bastida
JLJuan Pedro López-Siguero
Juan Pedro López-Siguero
JOJuan Oliva-Moreno
Juan Oliva-Moreno
MPMagaly Perez-Nieves
Magaly Perez-Nieves
RVRenata Villoro
Renata Villoro
LVLuis Alberto Vázquez
Luis Alberto Vázquez
To estimate the social-economic costs of Type 1 Diabetes Mellitus (T1DM) in patients aged 0-17years in Spain from a social perspective. We conducted a cross-sectional observational study in 2014 of 275 T1DM pediatric outpatients distributed across 12 public health centers in Spain. Data on demographic and clinical characteristics, healthcare utilization and informal care were collected from medical records and questionnaires completed by clinicians and patients' caregivers. A valid sample of 249 individuals was analyzed. The average annual cost for a T1DM patient was €27,274. Direct healthcare costs were €4070 and direct non-healthcare cost were €23,204. Informal (familial) care represented 83% of total cost, followed by medical material (8%), outpatient and primary care visits (3.1%) and insulin (2.1%). Direct healthcare cost per patient statistically differed by glycated haemoglobin (HbA1c) level [mean cost €4704 in HbA1c ≥7.5% (≥58mmol/mol) group vs. €3616 in HbA1c<7.5% (<58mmol/mol) group)]; and by the presence or absence of complications and comorbidities (mean cost €5713 in group with complications or comorbidities vs. €3636 in group without complications or comorbidities). T1DM amongst pediatric patients incurs in considerable societal costs. Informal care represents the largest cost category.

1 April 2016 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
LLLuis Pérez Pérez de Llano
Luis Pérez Pérez de Llano
RVRenata Villoro
Renata Villoro
MMMaría Merino
María Merino
MNMaria del Carmen Gómez Neira
Maria del Carmen Gómez Neira
CMCamino Muñiz
Camino Muñiz
ÁHÁlvaro Hidalgo
Álvaro Hidalgo

20 February 2018 in Journal of Asthma
Verified
Journal Article
Closed access
LLLuis Pérez Pérez de Llano
Luis Pérez Pérez de Llano
ASAbel Pallares Sanmartin
Abel Pallares Sanmartin
Francisco-Javier Gonzalez-BarcalaFrancisco-Javier Gonzalez-Barcala
Francisco-Javier Gonzalez-Barcala
MMMar Mosteiro-Añón
Mar Mosteiro-Añón
DADolores Corbacho Abelaira
Dolores Corbacho Abelaira
MVMaría Merino Ventosa
María Merino Ventosa
Introduction: This study was aimed at evaluating whether once-daily regimens (od-r) show benefits in adherence when compared to twice-daily (td-r). Methods: Prospective, multicenter, 6-month follow-up study with two visits. The main objective was to compare adherence assessed by the electronic prescription refill rate (EPRR) and by the 10-item Test of Adherence to Inhalers (TAI) in patients with od-r and td-r. Suboptimal adherence was defined as TAI < 50 or EPRR ≤ 80%. The effect of suboptimal adherence on meaningful clinical outcomes and the concordance between EPRR and TAI were also examined. Results: One hundred and ninety-seven patients (47.3 ± 15.9 years, 65% women) were included and 180 completed the study. TAI score was <50 in 29.8% od-r patients and 46.9% in td-r (p = 0.01) and EPRR was ≤80% in 22.6% and 37.5% respectively (p = 0.02). The correlation between the two methods was moderate (rho = 0.548; p < 0.001). There were no significant differences in FEV1 (%), symptoms or exacerbations between patients with optimal and suboptimal adherence. During follow-up, five patients (6%) with o-dr and 17 patients (17.7%) with t-dr suffered an exacerbation (p = 0.013). At visit two, 13.1% of the patients with o-dr and 31.3% with t-dr had uncontrolled asthma (p = 0.003), although more patients with o-dr were receiving inhaled corticosteroids in the high-dose stratum (25.8% vs. 11.5%; p = 0.001). Conclusion: Mean adherence rates were greater with od-r than with td-r, but we did not observe an effect on clinical outcomes.

9 April 2021 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
MMMaría Merino
María Merino
OBOlta Braçe
Olta Braçe
AGAlmudena González-Domínguez
Almudena González-Domínguez
ÁHÁlvaro Hidalgo-Vega
Álvaro Hidalgo-Vega
MGMarco Garrido-Cumbrera
Marco Garrido-Cumbrera
JGJordi Gratacós
Jordi Gratacós
Full Papers; Authors: M. Merino, O. Braçe, A. González-Domínguez, Á. Hidalgo-Vega, M. Garrido-Cumbrera, J. Gratacós

1 September 2016 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
RCRaquel Català
Raquel Català
RVRenata Villoro
Renata Villoro
MMMaría Merino
María Merino
SSSandra Sangenís
Sandra Sangenís
LCLluís Colomés
Lluís Colomés
LLLuis A. Pérez de Llano
Luis A. Pérez de Llano